- Home
- XPRO vs AUPH Comparison
XPRO vs AUPH Comparison
Compare XPRO & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPRO
- AUPH
- Stock Information
- Founded
- XPRO 1938
- AUPH 1993
- Country
- XPRO United States
- AUPH Canada
- Employees
- XPRO N/A
- AUPH N/A
- Industry
- XPRO Oilfield Services/Equipment
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- XPRO Energy
- AUPH Health Care
- Exchange
- XPRO Nasdaq
- AUPH Nasdaq
- Market Cap
- XPRO 1.4B
- AUPH 1.4B
- IPO Year
- XPRO 2013
- AUPH 1999
- Fundamental
- Price
- XPRO $12.42
- AUPH $12.40
- Analyst Decision
- XPRO Buy
- AUPH Strong Buy
- Analyst Count
- XPRO 4
- AUPH 4
- Target Price
- XPRO $12.50
- AUPH $12.25
- AVG Volume (30 Days)
- XPRO 1.1M
- AUPH 1.8M
- Earning Date
- XPRO 10-23-2025
- AUPH 07-31-2025
- Dividend Yield
- XPRO N/A
- AUPH N/A
- EPS Growth
- XPRO N/A
- AUPH N/A
- EPS
- XPRO 0.61
- AUPH 0.42
- Revenue
- XPRO $1,673,283,000.00
- AUPH $260,111,000.00
- Revenue This Year
- XPRO N/A
- AUPH $16.92
- Revenue Next Year
- XPRO $3.65
- AUPH $14.29
- P/E Ratio
- XPRO $20.67
- AUPH $29.81
- Revenue Growth
- XPRO 2.67
- AUPH 25.59
- 52 Week Low
- XPRO $6.70
- AUPH $6.42
- 52 Week High
- XPRO $18.76
- AUPH $12.82
- Technical
- Relative Strength Index (RSI)
- XPRO 63.38
- AUPH 66.76
- Support Level
- XPRO $11.92
- AUPH $11.57
- Resistance Level
- XPRO $12.64
- AUPH $12.46
- Average True Range (ATR)
- XPRO 0.46
- AUPH 0.37
- MACD
- XPRO -0.00
- AUPH -0.09
- Stochastic Oscillator
- XPRO 85.40
- AUPH 66.51
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.